Day: March 11, 2024

Business transformation continues; delivering record-setting new business wins in 2023 and significantly improved free cash flow performance Company provides sales, adjusted EBITDA, and free cash flow outlook for 2024 CHARLOTTE, N.C., March 11, 2024 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, today reported its financial results for the fourth quarter ended December 31, 2023. Financial and Strategic HighlightsDisplayed strong execution against the Company’s multi-year transformation plan, driving positive inflection in financial and operating results in the second half of the year; Delivered company record for new business awards of $62.6 million in 2023; Launched multiple long-term strategic initiatives to drive...

Dorel Juvenile’s turnaround continues; posts best quarter in more than 5 years Lower furniture industry sales dampen Dorel Home resultsMONTRÉAL, March 11, 2024 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) today announced results for the fourth quarter and the year ended December 30,2023.   Fourth quarter revenue from continuing operations was US$350.7 million, up 3.1%, from US$340.3 million a year ago. Reported net loss from continuing operations for the quarter was US$3.8 million or US$0.12 per diluted share compared to US$41.4 million or US$1.27 per diluted share a year ago. Adjusted net income1 from continuing operations was US$0.2 million or US$0.01 per diluted share compared to an adjusted net loss1 from continuing operations of US$39.8 million or US$1.22 per diluted share for the fourth quarter a year ago.   Revenue...

CHICAGO, March 11, 2024 (GLOBE NEWSWIRE) — Monroe Capital Corporation (Nasdaq: MRCC) (“Monroe”) today announced its financial results for the fourth quarter and full year ended December 31, 2023. Except where the context suggests otherwise, the terms “Monroe,” “we,” “us,” “our,” and “Company” refer to Monroe Capital Corporation. Fourth Quarter 2023 Financial HighlightsNet Investment Income of $5.3 million, or $0.24 per share Adjusted Net Investment Income (a non-GAAP measure described below) of $5.6 million, or $0.26 per share Net increase in net assets resulting from operations of $1.6 million, or $0.07 per share Net Asset Value (“NAV”) of $203.7 million, or $9.40 per share Paid quarterly dividend of $0.25 per share on December 29, 2023 Current annual cash dividend yield to shareholders of approximately 13.4% (1)Full Year...

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist, with top-line data anticipated by mid 2025 and H1 2026, respectively IND filings for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipated Q2 2024 and H2 2024, respectively Year end 2023 cash and investments of $417 million and reiterating cash runway through year-end 2026SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the...

– CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 – – CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) anticipated in the 1st half of 2024 – – CX-801 (IFNα2b) Phase 1 clinical study initiation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma anticipated in 1st half of 2024 –   – Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT – SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update. “2023 was a year...